drugset
drugset / Trial / NCT00077961

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

NCT00077961 ↗

Phase 1/2 Terminated 49 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used in combination with rituximab for patients with relapsing or refractory, low-grade or follicular, CD-20-positive, B-Cell non-Hodgkin's Lymphoma. Safety will be the primary objective of phase I, while the primary objective of phase II will be to determine overall response.

Timeline

Start
2003-12
Primary completion
2006-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody — Subcutaneous

Indications

non-Hodgkin lymphoma